Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study
Open accessPublished version of a preprint
The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Cotadutide, a dual GLP-1 and glucagon receptor agonist, is under development for nonalcoholic steatohepatitis (NASH) and chronic kidney disease with type 2 diabetes. The effects of cotadutide on hepatic and metabolic parameters were evaluated in participants with overweight/obesity and type 2 diabetes. RESEARCH DESIGN AND METHODS: In this phase 2b study, 834 adults with BMI ≥25 kg/m2 and type 2 diabetes inadequately controlled with metformin (glycated hemoglobin A1c [HbA1c] of 7.0%–10.5% [53–91 mmol/mol]) were randomized to double-blind cotadutide 100 μg (n = 100), 200 μg (n = 256), or 300 μg (n = 256); placebo (n = 110); or open-label liraglutide 1.8 mg (n = 110)—all administered subcutaneously. Coprimary end points were changes in HbA1c and body weight at week 14. The originally randomized interventions were continued to week 54. Liver damage biomarkers and liver fibrosis algorithms were assessed. RESULTS: Cotadutide significantly decreased HbA1c and body weight at weeks 14 and 54 versus placebo (all P < 0.001). Improvements in lipid profile, AST and ALT levels, propeptide of type III collagen level, fibrosis-4 index, and nonalcoholic fatty liver disease fibrosis score were observed with cotadutide 300 μg versus placebo, but not with liraglutide. Weight loss with cotadutide 200 μg was similar to that with liraglutide 1.8 mg and greater with cotadutide 300 μg versus liraglutide 1.8 mg. The most common adverse events with cotadutide (nausea, 35%; vomiting, 17%) decreased over time. CONCLUSIONS: Cotadutide treatment for 54 weeks improved glycemic control and weight loss in participants with overweight/obesity and type 2 diabetes. Ad hoc analyses demonstrated improvements in hepatic parameters and support further evaluation of cotadutide in NASH.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Cotadutide, but not liraglutide improved hepatic parameters and metabolic dysfunction-associated steatohepatitis (MASH) with similar weight loss with 200 μg cotadutide compared to 1.8 mg liraglutide and greater with 300 μg cotadutide versus 1.8 mg liraglutide [47].”
From The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update. (2024) · cites this paper as [47]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“cotadutide did induce a dose-dependent 4–8 times greater reduction in triglycerides over liraglutide.”
From Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes (2024) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The first GLP-1R/GCGR agonist to be put in clinical trials, cotadutide, produced comparable reductions in body weight and blood sugar levels in adults with overweight or obesity, and T2D as 1.8 mg of liraglutide [82].”
From Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes (2024) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Through a phase 2b trial, cotadutide 300 μg was shown to significantly improve liver injury enzymes, propeptide of type III collagen level, FIB-4, and NAFLD fibrosis score compared to placebo (but not compared to liraglutide) and reduce body weight more than treatment with liraglutide 1.8 mg.”
From GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives (2023) · cites this paper as [173]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Apart from combining existing drugs, the development of dual GLP-1/glucagon receptor or GLP-1/GIP agonists or even triagonists237 with first promising results in NASH237–239 may show up another promising approach in drug development.”
From Novel therapeutic targets for cholestatic and fatty liver disease (2022) · cites this paper as [239]
Experimental — accuracy not yet measured
10 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chalasani, N., Younossi, Z., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K., Charlton, M., & Sanyal, A. J. (2012) · Hepatology · doi:10.1002/hep.25762 · Cited by 3,803
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345 · cited 1×
“The pathology of NAFLD can progress further to nonalcoholic steatohepatitis (NASH), advanced fibrosis, and end-stage cirrhosis (7).”
BackgroundByrne, C. D., & Targher, G. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.12.012 · Cited by 3,042 · cited 1×
“Because the majority of deaths linked with NAFLD are attributable to cardiovascular disease, and given the close association between type 2 diabetes and NAFLD, therapeutic agents that improve both liver health and cardiometabolic risk are clinically valuable (36,37).”
BackgroundFox, C. S., Massaro, J. M., Hoffmann, U., Pou, K. M., Maurovich-Horvat, P., Liu, C.-Y., Vasan, R. S., Murabito, J. M., Meigs, J. B., Cupples, L. A., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.675355 · Cited by 2,882 · cited 1×
“Increased adipose tissue has been associated with increased cardiometabolic risk (43,44).”
BackgroundEinarson, T. R., Acs, A., Ludwig, C., & Panton, U. H. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0728-6 · Cited by 2,312 · cited 1×
“Increased adipose tissue has been associated with increased cardiometabolic risk (43,44).”
BackgroundNeuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
Armstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203
Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis
Promrat, K., Kleiner, D. E., Niemeier, H. M., Jackvony, E., Kearns, M., Wands, J. R., Fava, J. L., & Wing, R. R. (2010) · Hepatology · doi:10.1002/hep.23276 · Cited by 1,330 · cited 1×
“In previous studies of participants with obesity and NASH, weight loss achieved through lifestyle modifications decreased intrahepatic fat and ALT levels while improving hepatic fibrosis (32,33).”
BackgroundGLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311 · cited 1×
“Treatment with glucagon-like peptide 1 (GLP-1) receptor agonists has been shown to improve glycemic control (13), delay gastric emptying, and induce weight loss in people with type 2 diabetes (14,15).”
BackgroundDavies, M. J., Bergenstal, R., Bode, B., Kushner, R. F., Lewin, A., Skjøth, T. V., Andreasen, A. H., Jensen, C. B., DeFronzo, R. A., & for the NN8022-1922 Study Group (2015) · JAMA · doi:10.1001/jama.2015.9676 · Cited by 1,198
Cited by
Items 101–200 of 324
Goldenberg, R. M., Gilbert, J. D., Manjoo, P., Pedersen, S. D., Woo, V. C., & Lovshin, J. A. (2024) · Obesity Reviews · doi:10.1111/obr.13663 · Cited by 27
“44 There is considerable interest in the development of the unimole-cular GLP-1R/GIP/glucagon receptor triple agonist class (Figure 1).”
BackgroundMisra, A., Kumar, A., Kuchay, M. S., Ghosh, A., Gulati, S., Choudhary, N. S., Dutta, D., Sharma, P., Vikram, N. K., Rastogi, A., et al. (2025) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2025.103209 · Cited by 28
Glucagon and Its Receptors in the Mammalian Heart
Neumann, J., Hofmann, B., Dhein, S., & Gergs, U. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612829 · Cited by 32
Perspectives in weight control in diabetes - survodutide
Klein, T., Augustin, R., & Hennige, A. M. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110779 · Cited by 25
Recent advances in peptide-based therapies for obesity and type 2 diabetes
Bailey, C. J., Flatt, P. R., & Conlon, J. M. (2024) · Peptides · doi:10.1016/j.peptides.2024.171149 · Cited by 25
“Some other dual GLP-1/GCGR agonists have not been continued as potential anti-obesity agents (eg cotadutide and NN-1177) but may be considered for treat-ment of fatty liver [38].”
BackgroundAt the Crossroads of Health and Disease: Consequences of Fat in the Liver
Dukewich, M., Yuan, L., & Terrault, N. A. (2025) · Annual Review of Physiology · doi:10.1146/annurev-physiol-022724-105515 · Cited by 38
HFpEF and MASLD: converging mechanisms and clinical implications
Capone, F., Häseli, S. P., Liu, L., Strocchi, S., Langenberg, C., Lusis, A. J., Pietzner, M., Muoio, D. M., Rider, O. J., Raman, B., et al. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01257-z · Cited by 37
“…agonists (cotadutide, efinopeg-tudite and pemvidutide) improved markers of steatosis, inflammation and/or fibrosis in patients with MASLD and overweight or obesity, when compared with placebo (for pemvidutide and cotadutide) or with other GLP1R agonists (for cotadutide and efinopegdutide) 396–398 .”
Present and Future Perspectives in the Treatment of Liver Fibrosis
Cerrito, L., Galasso, L., Iaccarino, J., Pizzi, A., Termite, F., Esposto, G., Borriello, R., Ainora, M. E., Gasbarrini, A., & Zocco, M. A. (2025) · Pharmaceuticals · doi:10.3390/ph18091321 · Cited by 35
“…GLP-1 and glucagon receptor agonist) in the reduction in fibrosis scores in patients with MASLD ( p = 0.010), while liraglutide did not have the same outcomes regarding liver fibrosis, measured with fibrosis-4 (FIB-4) index and “non-alcoholic fatty liver disease” NAFLD fibrosis score (NFS) [170].”
InfluentialEmerging and Established Therapeutic Approaches for Nonalcoholic Fatty Liver Disease
Brown, E. E., Hydes, T., Hamid, A., & Cuthbertson, D. J. (2021) · Clinical Therapeutics · doi:10.1016/j.clinthera.2021.07.013 · Cited by 31
Holst, J. J., Jepsen, S. L., & Modvig, I. M. (2022) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2022.102189 · Cited by 29
Newer pharmacological interventions directed at gut hormones for obesity
Camilleri, M., & Acosta, A. J. (2023) · British Journal of Pharmacology · doi:10.1111/bph.16278 · Cited by 29
“Cotadutide is a dual incretin agonist (GLP-1/glucagon) that was efficacious in improving glycaemic control and reducing body weight in obese patients with type 2 diabetes (Nahra et al., 2021).”
BackgroundAli, M. M., Hafez, A., Abdelgalil, M. S., Hasan, M. T., El-Ghannam, M. M., Ghogar, O. M., Elrashedy, A. A., & Abd-ElGawad, M. (2022) · BMC Endocrine Disorders · doi:10.1186/s12902-022-01031-5 · Cited by 23
“Only 16% of participants acquired ADAs over a titer of 80, at which point the influence on pharmacokinetics was around two times higher than the population average [16] (ClinicalTrials.”
BackgroundThe current significance and prospects for the use of dual receptor agonism GLP-1/Glucagon
Spezani, R., & Mandarim-de-Lacerda, C. A. (2022) · Life Sciences · doi:10.1016/j.lfs.2021.120188 · Cited by 23
Muzurović, E. M., Katsiki, N., Volčanšek, Š., Plescia, F., Rizzo, M., & Mantzoros, C. S. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156494 · Cited by 25
Current and emerging medications for the management of obesity in adults
Walmsley, R., & Sumithran, P. (2023) · The Medical Journal of Australia · doi:10.5694/mja2.51871 · Cited by 25
Heckmann, N. D., Palmer, R. C., Mayfield, C. K., Gucev, G., Lieberman, J. R., & Hong, K. M. (2024) · Arthroplasty Today · doi:10.1016/j.artd.2024.101327 · Cited by 22
Dual gut hormone receptor agonists for diabetes and obesity
Bass, J., Tschöp, M. H., & Beutler, L. R. (2023) · Journal of Clinical Investigation · doi:10.1172/jci167952 · Cited by 21
Ma, J., Hu, X., Zhang, W., Tao, M., Wang, M., & Lu, W. (2024) · Endocrine · doi:10.1007/s12020-024-03998-8 · Cited by 21
“In previous clinical trials exploring cotadutide, a GLP-1/GCG dual agonist, reductions in both HbA1c levels and body weight were observed [34].”
Chrysavgis, L., Kazanas, S., Bafa, K., Rozani, S., Koloutsou, M. E., & Cholongitas, Ε. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073832 · Cited by 26
“The beneficial effects of dual incretin agonists were verified by another randomized, double-blind, placebo-controlled phase 2b study, in which cotadutide, a dual GLP-1 and GCG RA, was evaluated for its hepatic effect in obese patients with T2DM [106].”
BackgroundResultInfluentialValdecantos, M. P., Ruiz, L., Folgueira, C., Rada, P., Gómez‐Santos, B., Solas, M., Hitos, A. B., Field, J., Francisco, V., Escalona-Garrido, C., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54080-w · Cited by 24
“In a phase 2b trial, cotadutide reduced glycemia and body weight and improved metabolic-dysfunction associated steatotic liver disease (MASLD) 18 .”
Self-citationKakazu, E., Mino, M., & Kanto, T. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.0048 · Cited by 28
Salmen, T., Șerbănoiu, L. I., Bica, I.-C., Serafinceanu, C., Muzurović, E. M., Janež, A., Busnatu, Ș., Banach, M., Rizvi, A. A., Rizzo, M., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119760 · Cited by 25
“…and cagrilintide, that in phase 2 studies provided a higher HbA1c and BW reduction compared to both its components [86], while cotadutide bamadutide and SAR425899, dual GLP-1 and glucagon receptor agonists, reduced HbA1c along with BW in patients with T2DM and who are overweight or obese [87,88].”
ResultFinan, B., Douros, J. D., Goldwater, R., Hansen, A. M. K., Hjerpsted, J., Hjøllund, K. R., Kankam, M. K., Knerr, P. J., Konkar, A. A., Mowery, S. A., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102129 · Cited by 21
“JNJ-64565111 showed signi fi cant weight reduction but no improvement in glycemic parameters, while cotadutide demonstrated signi fi cant reductions in both body weight and HbA 1c vs placebo in individuals with T2D and overweight or obesity [14,16,19].”
Camilleri, M. (2023) · Neurogastroenterology & Motility · doi:10.1111/nmo.14660 · Cited by 25
“64 Cotadutide resulted in significant weight loss 65 and retarded gastric emptying measured by 13 C-octanoic acid breath test during a 50-day study that had the advantage of repetitive measurements of gastric emptying of solid food with the stable isotope breath test at baseline, Days 15, 29, 43,…”
MethodPharmacological management of pediatric metabolic dysfunction‐associated steatotic liver disease
Jaoudeh, R. A. R. A., Hartmann, P., Olson, O., Gupta, O. T., Kumar, S., Ibrahim, S. H., Fawaz, R. L., Aqul, A. A., & Hassan, S. M. (2024) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1002/jpn3.12402 · Cited by 23
Pharmacological modulation of adaptive thermogenesis: new clues for obesity management?
Genchi, V. A., Palma, G., Sorice, G. P., D’Oria, R., Caccioppoli, C., Marrano, N., Biondi, G., Caruso, I., Cignarelli, A., Natalicchio, A., et al. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02125-0 · Cited by 23
“These promising results encouraged the development of more suitable synthetic dual agonists, such as cotadutide and the more recent mazdutide, which successfully reduced body weight in exploratory analysis of obese and T2D patients [222, 223].”
BackgroundPotential Therapeutic Strategies in the Treatment of Metabolic-Associated Fatty Liver Disease
Bołdys, A., Bułdak, Ł., Maligłówka, M., Surma, S., & Okopień, B. (2023) · Medicina · doi:10.3390/medicina59101789 · Cited by 25
“[48].”
The role of incretin receptor agonists in the treatment of obesity
Forst, T. M., Block, C. E. M. D., Prato, S. D., Armani, S., Frías, J. P., Lautenbach, A., Ludvik, B. H., Marinez, M., Mathieu, C., Müller, T. D., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15796 · Cited by 22
“111,112 However, the manufacturer has terminated the clinical programme for once-daily cotadutide in favour of AZD9550, a once-weekly injectable GLP-1 receptor/glucagon agonist.”
Translational aspects of glucagon: current use and future prospects
Kaur, J., & Seaquist, E. R. (2023) · Journal of Endocrinology · doi:10.1530/joe-22-0278 · Cited by 21
Stefanakis, K., Kokkinos, A. D., Argyrakopoulou, G., Konstantinidou, S. M., Simati, S., Kouvari, M., Kumar, A., Kalra, B., Kumar, M., Bontozoglou, N., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15141 · Cited by 19
“However, in healthy humans with normal weight or obesity, GLP-1 (9–36) and (7–36) failed to alter GLP-1 (7-36), GLP-2 or peptide-YY (PYY) levels through a transient infusion.”
BackgroundInfluentialXie, C., Alkhouri, N., & Elfeki, M. A. (2024) · World Journal of Hepatology · doi:10.4254/wjh.v16.i5.731 · Cited by 23
Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article
Sidrak, W. R., Kalra, S., & Kalhan, A. (2024) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_442_23 · Cited by 27
“[64] • Due to strategic pipeline considerations, the development of Cotadutide has been discontinued in favour of focusing on AZD9550, a once‑weekly injectable GLP1RA/GCGR. AstraZeneca will shift its focus to the ever‑growing diabetes and obesity market due to the increased utilization of GLP1RA…”
Zhihong, Y., Chen, W., Qianqian, Z., Lidan, S., Zhou, Q., Han, J. D. J., Wenxi, W., & Bhawal, R. P. (2023) · Peptides · doi:10.1016/j.peptides.2023.170955 · Cited by 18
Pharmacotherapy for obesity: recent evolution and implications for cardiovascular risk reduction
Maki, K. C., Kirkpatrick, C. F., Allison, D. B., & Gadde, K. M. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2209176 · Cited by 19
“weeks in patients with overweight or obesity and T2D [73].”
BackgroundSelf-citationMonfeuga, T., Norlin, J., Bugge, A. K., Galsgaard, E. D., Prada‐Medina, C. A., Latta, M. R., Veidal, S. S., Petersen, P. S., Feigh, M., & Holst, D. (2023) · Molecular Metabolism · doi:10.1016/j.molmet.2023.101850 · Cited by 18
“Several of the compounds tested in clinical trials so far, has failed to achieve a signi fi cant body weight loss [20].”
BackgroundGolubić, R., Kennet, J., Parker, V., Robertson, D. C., Luo, D., Hansen, L. B., Jermutus, L., Ambery, P., Ryaboshapkina, M., Surakala, M., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15579 · Cited by 21
“34 Clinical studies of cotadutide in obese or overweight individuals with T2D demonstrated decreased body weight and improvements in glycaemia, 5,25,35 with the latter being mediated by increased insulin secretion and delayed gastric emptying.”
BackgroundSelf-citationGut hormone multi-agonists for the treatment of type 2 diabetes and obesity: advances and challenges
Huang, X., Liu, J., Peng, G., Lu, M., Zhou, Z., Jiang, N., & Yan, Z. (2024) · Journal of Endocrinology · doi:10.1530/joe-23-0404 · Cited by 20
GLP-1/GIP/glucagon receptor triagonism gets its try in humans
Finan, B., & Douros, J. D. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2021.12.010 · Cited by 17
Soresi, M., & Giannitrapani, L. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v30.i30.3541 · Cited by 20
“For example, Cotadutide, a dual GLP-1 and glucagon receptor agonist, has been studied in overweight or obese and T2DM subjects [15], and is now under development for NASH (NCT04019561).”
Jeyakumar, Y., Richardson, L., Sarma, S., Retnakaran, R. R., & Kramer, C. K. (2024) · BMJ Global Health · doi:10.1136/bmjgh-2024-017177 · Cited by 21
Wen, J., Nadora, D., Truong, A., Bernstein, E., How-Volkman, C., Razick, A. A., Razick, D., Karabala, M., & Frezza, E. (2025) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2025.104213 · Cited by 20
Malik, I. O., Petersen, M. C., & Klein, S. (2022) · Obesity · doi:10.1002/oby.23521 · Cited by 18
Ten reasons gastroenterologists and hepatologists should be treating obesity
Camilleri, M., & El-Omar, E. M. (2023) · Gut · doi:10.1136/gutjnl-2023-329639 · Cited by 18
Therapeutics for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
Bhopale, K. K., & Srinivasan, M. P. (2023) · Livers · doi:10.3390/livers3040040 · Cited by 19
Weight Loss Blockbuster Development: A Role for Unimolecular Polypharmacology
Zhou, Q., Li, G., Hang, K., Li, J., Yang, D., & Wang, M. (2024) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-061324-011832 · Cited by 16
Hope, D. C. D., & Tan, T. M.-M. (2023) · Peptides · doi:10.1016/j.peptides.2023.170962 · Cited by 16
Wu, Y., Dong, P., Wu, Q., Zhang, Y., Xu, G., Pan, C., & Tong, H. (2025) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3606 · Cited by 20
“44 In comparison to high-dose GLP-1R agonists alone, dual and triple receptor agonists may exert additional impacts on the histological features of MASH, potentially independent of body weight changes.”
Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Causation or Association
Bali, A. D., Rosenzveig, A., Frishman, W. H., & Aronow, W. S. (2023) · Cardiology in Review · doi:10.1097/crd.0000000000000537 · Cited by 18
Ye, X., Chen, Y., Qi, J., Zhu, S., Wu, Y., Xiong, J., Hu, F., Guo, Z., & Liang, X. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175811 · Cited by 14
Challenging Clinical Perspectives in Type 2 Diabetes with Tirzepatide, a First-in-Class Twincretin
MacIsaac, R. J., Deed, G., dʼEmden, M. C., Ekinci, E. I., HOCKING, S. L., Sumithran, P., & Rasalam, R. R. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01475-5 · Cited by 17
“Gastrointestinal disorders were the most commonly reported adverse event; these occurred more frequently with cotadutide than with liraglutide or placebo, but incidence decreased over time [59].”
BackgroundMethodInfluentialPoly-Agonist Pharmacotherapies for Metabolic Diseases: Hopes and New Challenges
Allard, C., Cota, D., & Quarta, C. (2023) · Drugs · doi:10.1007/s40265-023-01982-6 · Cited by 17
“Cotadutide, the first GLP-1R-GCGR co-agonist in clinical development by Astra-Zeneca, improved glycaemic control and weight loss in participants with overweight/obesity and T2D over 54 weeks of treatment [144].”
Suba, K., Patel, Y., Alonso, A. M., Hansen, B., Xu, X., Roberts, A. G., Norton, M., Chung, P., Shrewsbury, J. V., Kwok, R., et al. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.101947 · Cited by 23
“As an example, cotadutide is currently being tested in Phase 2 clinical trials following its promising effects on DIO mice and non-human primates [48].”
BackgroundDeng, B., Ruan, T., Lu, W., Ying, J., Li, S., Zhou, R., & Mu, D. (2024) · Endocrine · doi:10.1007/s12020-024-03857-6 · Cited by 19
Xia, Y., Gao, Z., Yang, C., Duan, K., Ren, L., & Song, G. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1170881 · Cited by 17
Stefanakis, K., Kokkinos, A. D., Simati, S., Argyrakopoulou, G., Konstantinidou, S. M., Kouvari, M., Kumar, A., Kalra, B., & Mantzoros, C. S. (2023) · Clinical Nutrition · doi:10.1016/j.clnu.2023.06.026 · Cited by 14
Therapeutic Potential of GLP-1 Receptor Agonists in Metabolic Associated Steatotic Liver Disease
Nowak, K., Łupina, K., Romac, A., Kalisz, A., Ilkiewicz, Ł., & Janczura, J. (2025) · Annals of Pharmacotherapy · doi:10.1177/10600280251322002 · Cited by 21
Ahmad, N., Alruwayyes, A., AlArjani, A., Tawhari, A. M., Aldosri, A., Alahmari, A., & Balaha, M. F. H. (2026) · Medicine · doi:10.1097/md.0000000000047994 · Cited by 18
“…al [31] Randomized Low risk Low risk Low risk Low risk Low risk Dahl et al [32] Randomized Low risk Low risk Low risk Low risk Low risk Nahra et al [33] Randomized Low risk 26% attrition Low risk Low risk High risk Rubino et al [34] Randomized Low risk Low risk Low risk Low risk Low risk Wadden et…”
InfluentialLaker, R. C., Egolf, S., Will, S., Lantier, L., McGuinness, O. P., Brown, C. L., Bhagroo, N. V., Oldham, S. N., Kuszpit, K. K., Alfaro, A., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59773-4 · Cited by 18
“…fi cantly reduced liver fat content by MRI-PDFF (magnetic resonance imaging-proton density fat fraction) as well as signi fi cant reductions in circulating collagen fragment, Pro-C3, as a biomarker for liver fi brosis activity and in the FIB4 index, a risk-factor score for fi brosis 11,12,56 – 59 .”
InfluentialCo-agonist therapeutics come of age for obesity
Tan, T. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00788-y · Cited by 13
Asano, M., Sekikawa, A., Sugeno, M., Matsuoka, O., Robertson, D. C., & Hansen, L. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15107 · Cited by 13
Alonso‐Peña, M., Barrio, M. D., Peleteiro‐Vigil, A., Jiménez-González, C., Santos‐Laso, Á., Arias, M., Iruzubieta, P., & Crespo, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310718 · Cited by 19
Biology and Clinical Use of Glucagon-Like Peptide-1 Receptor Agonists in Vascular Protection
Yau, K., Odutayo, A., Dash, S., & Cherney, D. Z. I. (2023) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2023.07.007 · Cited by 21
Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes
Guo, L., Zhang, B., Xue, X., Zhang, B., Cai, H., Jiang, H., Zhang, L., Jin, P., Wang, X., Cheng, Z., et al. (2025) · Nature · doi:10.1038/s41586-025-10031-z · Cited by 21
Targeting Gut–Liver Axis for Treatment of Liver Fibrosis and Portal Hypertension
Kalo, E., Read, S. A., & Ahlenstiel, G. (2021) · Livers · doi:10.3390/livers1030014 · Cited by 13
Obesity–An Update on the Basic Pathophysiology and Review of Recent Therapeutic Advances
Gjermeni, E., Kirstein, A., Kolbig, F., Kirchhof, M., Bundalian, L., Katzmann, J. L., Laufs, U., Blüher, M., Garten, A., & Duc, D. L. (2021) · Biomolecules · doi:10.3390/biom11101426 · Cited by 154
Breakthrough in the Treatment of Metabolic Associated Steatotic Liver Disease: Is it all over?
Petroni, M. L., Perazza, F., & Marchesini, G. (2024) · Digestive and Liver Disease · doi:10.1016/j.dld.2024.04.021 · Cited by 14
Yan, K., Yu, H., & Blaise, B. (2025) · Acta Diabetologica · doi:10.1007/s00592-025-02534-y · Cited by 20
“Cotadutide targets GLP-1 and glucagon recep - tors, which may lead to gastrointestinal side effects similar to those commonly observed with GLP-1 agonists, such as nausea and vomiting [16, 33].”
Perspectives in weight control in diabetes – SGLT2 inhibitors and GLP-1–glucagon dual agonism
Iqbal, N., Ambery, P., Logue, J., Mallappa, A., & Sjöström, C. D. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110669 · Cited by 14
Self-citationGlucagon-based therapy for people with diabetes and obesity: What is the sweet spot?
McGlone, E. R., & Tan, T. (2024) · Peptides · doi:10.1016/j.peptides.2024.171219 · Cited by 11
“The addition of GCGR to GLP-1R agonism does not worsen glycemia in comparative trials performed to date [66,70,73]; there is some evidence, however, that compounds with high GCGR activity may not improve measures of diabetes and could even lead to hyperglycemia [72,92].”
BackgroundInfluentialIncretin-based therapy: a new horizon in diabetes management
Zarei, M., Vaighan, N. S., Farjoo, M. H., Talebi, S., & Zarei, M. (2024) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01479-3 · Cited by 13
Characterization of LY3324954 a long-acting glucagon-receptor agonist
Roell, W. C., Coşkun, T., Kim, T., O’Farrell, L. S., Martin, J. A., Nason, S. R., Hernandez-Alamillo, J., Dhantu, S., Drucker, D. J., Sloop, K. W., et al. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.102073 · Cited by 12
“Collectively these studies provide deeper mechanistic understanding to the bene fi ts observed in GCGR-based coagonists [23 e 25,27,42].”
Liu, L., Rashid, M., & Wess, J. (2025) · Biochemistry · doi:10.1021/acs.biochem.4c00867 · Cited by 16
Zhang, J., Sanan, S., Csanalosi, M., Zheng, C., & Pfeiffer, A. F. H. (2025) · Endocrinology · doi:10.1210/endocr/bqaf130 · Cited by 15
Huangfu, G., Jaltotage, B., Pang, J., Lan, N. S. R., Abraham, A., Otto, J. H., Ihdayhid, A. R., Rankin, J. M., Chow, B. J. W., Watts, G. F., et al. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155370 · Cited by 12
Computational Peptide Design Cotargeting Glucagon and Glucagon-like Peptide-1 Receptors
Vishnoi, S., Bhattacharya, S., Walsh, E. M., Okoh, G., & Thompson, D. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.3c00752 · Cited by 13
Advances in obesity pharmacotherapy; learning from metabolic surgery and beyond
Tsilingiris, D., & Kokkinos, A. D. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155741 · Cited by 16
The Genetic Blueprint of Obesity: From Pathogenesis to Novel Therapies
Tonin, G., Eržen, S., Mlinarič, Z., Jurišić‐Eržen, D., Horvat, S., Kunej, T., & Klen, J. (2025) · Obesity Reviews · doi:10.1111/obr.13978 · Cited by 17
Jiang, N., Su, D., Chen, D., Huang, S., Tang, C., Jing, L., Yang, C.-Y., Zhou, Z., Yan, Z., & Han, J. D. J. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01049 · Cited by 10
Bosch, R., Petrone, M., Arends, R., Vicini, P., Sijbrands, E. J. G., Hoefman, S., & Snelder, N. (2024) · British Journal of Pharmacology · doi:10.1111/bph.16336 · Cited by 11
“Clinical studies repeatedly showed significantly improved postprandial glucose control and reduced bodyweight, compared with placebo (Ambery et al., 2018; Nahra et al., 2021; Parker et al., 2020; Parker et al., 2022).”
BackgroundType 2 diabetes: a sacrifice program handling energy surplus
Ye, J., & Yin, J. (2024) · Life Metabolism · doi:10.1093/lifemeta/loae033 · Cited by 9
Cazac, G.-D., Lăcătușu, C.-M., Grigorescu, E.-D., Foșălău, A.-B., Onofriescu, A., & Mihai, B. M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041042 · Cited by 10
“In a 54-week phase 2b trial, cotadutide was associated with favorable changes in body weight, serum alanine aminotransferase (ALT) levels, and markers of hepatic steatosis and fibrosis (NAFLD Fibrosis Score—NFS and Fibrosis-4 Index—FIB-4) in patients with NASH and T2DM [87].”
Steatotic Liver Disease in Older Adults: Clinical Implications and Unmet Needs
Clayton‐Chubb, D., Kemp, W. W., Majeed, A., Lange, P. W., Fitzpatrick, J. A., Vaz, K., Lubel, J. S., Hodge, A. D., Ryan, J. L., McNeil, J. J., et al. (2025) · Nutrients · doi:10.3390/nu17132189 · Cited by 14
Stachteas, P., Nasoufidou, A., Karakasis, P., Koiliari, M., Karagiannidis, E., Koufakis, T., Fragakis, N., & Patoulias, D. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm39691 · Cited by 11
“Specifically, those treated with cotadutide achieved a mean weight loss of approximately 5.1%, while the placebo group had a weight loss of about 1.2% [48].”
InfluentialIs polypharmacy the future for pharmacological management of obesity?
Lafferty, R. A., Flatt, P. R., & Irwin, N. (2022) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2022.100322 · Cited by 12
GLP-1 receptor agonists in the treatment of diabetic non–alcoholic steatohepatitis patients
Adeghate, E. A. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2328796 · Cited by 10
Novel Drugs for Diabetes Therapy
Heise, T. (2022) · Handbook of experimental pharmacology · doi:10.1007/164_2021_574 · Cited by 12
Li, L., Zhai, S., Wang, R., Kong, F., Yang, A., Wang, C., Yu, H., Li, Y., & Wang, D. (2023) · Nutrients · doi:10.3390/nu15040872 · Cited by 9
“Both AST and total cholesterol can serve as evaluation indices in patients with obesity, reflecting the degree of hepatocyte damage and increase in adipocytes [39,40].”
BackgroundCazac, G.-D., Lăcătușu, C.-M., Ștefănescu, G., Mihai, C., Grigorescu, E.-D., Onofriescu, A., & Mihai, B. M. (2023) · Metabolites · doi:10.3390/metabo13050581 · Cited by 10
Polyagonists in Type 2 Diabetes Management
Dissanayake, H. A., & Somasundaram, N. P. (2024) · Current Diabetes Reports · doi:10.1007/s11892-023-01530-2 · Cited by 8
Management of patients with type 2 diabetes and MASLD: An overview and joint statement
Chouik, Y., Canivet, C. M., Julla, J., Mouillot, T., Parlati, L., Rouland, A., Smati, S., Tramunt, B., Anty, R., Boursier, J., et al. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101709 · Cited by 12
Kowalska, M. K., El‐Mallul, A., Hudecka, W., Lubojańska, J. E., Lubojański, P. J., Orłowska, S. M., & Bednarczyk, Ł. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27041886 · Cited by 10
A review: Anti-obesity drug discovery from natural plant metabolites and endogenous peptides
Zhu, X., Wang, D., & Atanasov, A. G. (2024) · Current Research in Biotechnology · doi:10.1016/j.crbiot.2024.100259 · Cited by 9
Focus on Glucagon-like Peptide-1 Target: Drugs Approved or Designed to Treat Obesity
Zhang, J., Wei, J., Lai, W., Sun, J., Bai, Y., Cao, H., Guo, J., & Su, Z. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26041651 · Cited by 9
“It was well tolerated [61,62].”
Corrao, S., Falcone, F., Mirarchi, L., Amodeo, S., & Calvo, L. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01761-4 · Cited by 13
“Early-phase trials indicate that these agents may offer superior efficacy in reducing HbA1c and promoting diabetes remission compared to current GLP-1 receptor agonists [60, 61].”
Wang, H., Fan, K., Ning, Y., Li, Y., Qi, X., Wang, Z., Xu, K., Zhang, R., Zhou, Y., Dong, H., et al. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s538554 · Cited by 10
Updates on Anti-Obesity Medications in Children and Adolescents
Salama, M., Hassan, D., & Kumar, S. (2025) · Children · doi:10.3390/children12101390 · Cited by 10
“The study also reported favorable changes in lipid parameters, alanine aminotransferase (ALT), aspartate aminotransferase (AST), procollagen type III peptide, and metabolic dysfunction-associated steatotic liver disease (MASLD) scores [97].”
Tsakiridis, E. E., & Steinberg, G. R. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70624 · Cited by 9
“Other dual agonists, including cotadutide [166], efinopegdutide [167] and pemvidutide [168], have also shown reductions in liver fat and improvements in non-invasive markers of hepatic inflammation in early clinical studies, but histologic data remain limited.”
Klein, G., Petrone, M., Yang, Y., Hoang, T., Hazlett, S., Hansen, L. B., & Flor, A. (2023) · Clinical Pharmacokinetics · doi:10.1007/s40262-023-01239-1 · Cited by 7
Morales, E., Martin, W. P., Bevc, S., Jenssen, T. G., Miglinas, M., & Trillini, M. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf069 · Cited by 8
“There is emerging evidence of the efficacy on weight reduction of dual GLP-1R/glucagon receptor (GCGR) agonists (cotadutide, mazdutide, survodutide) [58 –60 ] and triple GLP-1R/GIP receptor/GCGR agonists (retatrutide) in overweight/obese individuals with or without diabetes.”
State-of-the-Art Overview of the Pharmacological Treatment of Non-Alcoholic Steatohepatitis
Cho, Y., & Lee, Y. (2022) · Endocrinology and Metabolism · doi:10.3803/enm.2022.102 · Cited by 8
Metadata
- Authors
- Nahra, R., Wang, T., Gadde, K. M., Oscarsson, J., Stumvoll, M., Jermutus, L., Hirshberg, B., & Ambery, P.
- Affiliations
- AstraZeneca (United States) (US)
- Pennington Biomedical Research Center (US)
- AstraZeneca (Sweden) (SE)
- 5Division of Endocrinology, University Hospital Leipzig, Leipzig, Germany
- AstraZeneca (United Kingdom) (GB)
- 4Clinical Metabolism, Late-stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
- Corresponding author
- Nahra, Rajaa
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2021-06-01
- Volume
- 44
- Issue
- 6
- Pages
- 1433-1442
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC8247525
- OpenAlex
- W3160773731
- Semantic Scholar
- 0019fb9a1c6044e014f9a7ae0dd18ea9907668eb
- Cited by
- 323
- References
- 47
- Citations by year
- 2026: 36 · 2025: 65 · 2024: 76 · 2023: 83 · 2022: 48 · 2021: 14
- FWCI
- 41.25
- Type
- journal article
- Language
- en
- Update notices
- correction (2022-10-13)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- AstraZeneca
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- GLP-1 receptor agonists, glucagon receptor agonist, type 2 diabetes, obesity, overweight, glycemic control, HbA1c, weight loss, non-alcoholic fatty liver disease, liver fibrosis, liver injury biomarkers, liraglutide, lipid profile, adverse events, nausea and vomiting, dose comparison
- MeSH terms
- Liraglutide, Adult, Blood Glucose, Diabetes Mellitus, Type 2, Double-Blind Method, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Liver, Obesity, Peptides, Overweight, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.